Stock Yards Bank & Trust Co. Has $13.89 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Stock Yards Bank & Trust Co. cut its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 0.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 234,684 shares of the biopharmaceutical company’s stock after selling 179 shares during the period. Stock Yards Bank & Trust Co.’s holdings in Bristol-Myers Squibb were worth $13,887,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the company. OLD Mission Capital LLC acquired a new position in Bristol-Myers Squibb during the third quarter valued at $234,000. Hoylecohen LLC raised its position in Bristol-Myers Squibb by 80.0% during the first quarter. Hoylecohen LLC now owns 113,661 shares of the biopharmaceutical company’s stock valued at $7,175,000 after buying an additional 50,521 shares during the period. Childress Capital Advisors LLC raised its position in Bristol-Myers Squibb by 67.9% during the first quarter. Childress Capital Advisors LLC now owns 7,995 shares of the biopharmaceutical company’s stock valued at $504,000 after buying an additional 3,234 shares during the period. Regency Capital Management Inc. DE acquired a new position in Bristol-Myers Squibb in the 1st quarter worth about $43,000. Finally, Aspire Private Capital LLC increased its position in Bristol-Myers Squibb by 3.4% in the 1st quarter. Aspire Private Capital LLC now owns 5,868 shares of the biopharmaceutical company’s stock worth $370,000 after purchasing an additional 192 shares during the last quarter. 72.07% of the stock is currently owned by institutional investors.

NYSE:BMY traded down $0.64 during mid-day trading on Thursday, hitting $56.81. 17,685,249 shares of the company’s stock traded hands, compared to its average volume of 10,797,460. The firm has a 50 day moving average of $58.78 and a two-hundred day moving average of $63.83. Bristol-Myers Squibb has a 12 month low of $56.11 and a 12 month high of $69.75. The firm has a market capitalization of $126.10 billion, a price-to-earnings ratio of -23.67, a price-to-earnings-growth ratio of 1.08 and a beta of 0.61. The company has a current ratio of 1.47, a quick ratio of 1.36 and a debt-to-equity ratio of 1.06.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Tuesday, October 26th. The biopharmaceutical company reported $2.00 earnings per share for the quarter, beating the consensus estimate of $1.92 by $0.08. The firm had revenue of $11.62 billion during the quarter, compared to the consensus estimate of $11.52 billion. Bristol-Myers Squibb had a positive return on equity of 43.05% and a negative net margin of 11.89%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.63 EPS. As a group, equities research analysts expect that Bristol-Myers Squibb will post 7.52 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Monday, November 1st. Investors of record on Friday, October 1st were issued a dividend of $0.49 per share. The ex-dividend date was Thursday, September 30th. This represents a $1.96 dividend on an annualized basis and a yield of 3.45%. Bristol-Myers Squibb’s dividend payout ratio is -81.67%.

BMY has been the topic of several research reports. BMO Capital Markets initiated coverage on Bristol-Myers Squibb in a research report on Thursday, November 18th. They issued an “outperform” rating and a $72.00 target price on the stock. Barclays dropped their target price on Bristol-Myers Squibb from $68.00 to $66.00 and set an “equal weight” rating on the stock in a research report on Thursday, October 28th. Truist initiated coverage on Bristol-Myers Squibb in a research report on Wednesday, July 28th. They issued a “buy” rating and a $74.00 target price on the stock. Morgan Stanley dropped their target price on Bristol-Myers Squibb from $71.00 to $66.00 and set an “equal weight” rating on the stock in a research report on Tuesday, October 12th. Finally, TheStreet upgraded Bristol-Myers Squibb from a “c+” rating to a “b” rating in a research note on Wednesday, November 17th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Bristol-Myers Squibb presently has an average rating of “Buy” and a consensus price target of $69.20.

In other Bristol-Myers Squibb news, EVP Autenried Paul Von sold 18,363 shares of Bristol-Myers Squibb stock in a transaction dated Monday, November 22nd. The stock was sold at an average price of $57.17, for a total value of $1,049,812.71. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Giovanni Caforio sold 25,000 shares of Bristol-Myers Squibb stock in a transaction dated Monday, September 20th. The shares were sold at an average price of $60.64, for a total value of $1,516,000.00. The disclosure for this sale can be found here. Insiders sold a total of 60,716 shares of company stock worth $3,553,545 over the last quarter. Corporate insiders own 0.11% of the company’s stock.

Bristol-Myers Squibb Profile

Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Further Reading: ESG Score

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.